Global first in Southampton for surgical device study

Southampton surgeons are the first in the world to trial a new surgical device.  

The trial is investigating a technology for use in keyhole surgery procedures.

Over 165 people entering surgery with the device will take part in the United Kingdom, United States and Canada.

A global trial

The device being tested is the HARMONIC™ 700.

It is an electrosurgical instrument designed to cut and seal blood vessels, as well as cut, grasp, and dissect tissue. It is already used for both open and keyhole surgery.

All patients taking part will have a medical condition requiring a general, gastrointestinal, gynaecological, urological or thoracic surgical procedure.

Mr Malcolm West is leading the recruitment of patients to the trial at University Hospital Southampton.

His research forms part of the Perioperative and Critical Care theme at the NIHR Southampton Biomedical Research Centre.

Assessing safety and performance

The study will gather data to assess the safety and performance of the HARMONIC 700 device.

Mr West, Associate Professor in Colorectal Surgery and Prehabilitation Medicine at the University of Southampton, said:

“It is fantastic that we are the first in the world to recruit a patient to this study. I would like to thank our whole team for making this huge achievement happen.

“This research will provide new data that will help to inform surgeons’ decisions on how and when to use this device, ensuring the care we provide is based on the latest evidence.”

Professor Andrew Ustianowski, Interim Executive Director of the NIHR Regional Delivery Network, said:

“First global recruitment is a significant achievement and one which is only delivered through effective and well managed feasibility and study set-up, reflecting the dedication and efforts of colleagues in Southampton.

“The UK is making significant progress in building its research capability and performance reputation for the life-sciences industry. Accomplishments such as the first global participation are testament to our ability to deliver research and opportunities for patients, carers and the public.”